The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Long-term efficacy of first-line ibrutinib for CLL: a pooled analysis from 4 trials
John Allan, MD, Weill Cornell Medicine, New York, NY, outlines the results of a pooled analysis of four clinical trials investigating the long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukemia (CLL) with a four-year follow-up of patients with TP53 aberrations. The clinical trials included in the analysis were PCYC-1122e (NCT01500733), PCYC-1130 (NCT02264574), E1912 (NCT02048813) and RESONATE-2 (NCT01722487). The analysis found that first-line ibrutinib-based treatment resulted in sustained efficacy with high progression-free survival (PFS) and overall survival (OS) rates in CLL patients with TP53 aberrations. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
John Allan, MD, has done consultancy work, participated in advisory boards and/or received honoraria from Pharmacyclics, Janssen, Abbvie, BeiGene, Genentech and AstraZeneca; and has received research Funding from Genentech, Janssen and TG Therapeutics.
